@article{767aae7a9fe34087983c65e2e038bf34,
title = "A phase I dose escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) in combination with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced solid tumors.",
author = "Segal, \{Neil Howard\} and Hodi, \{F. Stephen\} and Sanborn, \{Rachel E.\} and Thomas Gajewski and Wolchok, \{Jedd D.\} and Urba, \{Walter John\} and Fox, \{Bernard A.\} and Topalian, \{Suzanne Louise\} and Pardoll, \{Drew M.\} and Georgia Kollia and Dan McDonald and Kim, \{Su Young\} and Sharfman, \{William Howard\}",
note = "Background: Killer cell immunoglobulin-like receptor (KIR) and programmed death-1 (PD-1) are immune receptors that downregulate natural killer (NK) cell and T-cell activity, respectively. Immune checkpoint blockade is emerging as a novel form of cancer immunotherapy. Lirilumab, an anti-KIR antibody, potentiates NK activity and innate immunity, with only modest side effects (mostly grade 1 or 2) in a phase I monotherapy trial.",
year = "2014",
month = may,
day = "20",
language = "American English",
volume = "32",
journal = "Journal of Clinical Oncology",
}